UNIT 13B.1 Evaluation of Compound Activity Against Hepatitis C Virus in Replicon Systems

  1. Guangwei Yang,
  2. Mingjun Huang

Published Online: 1 SEP 2010

DOI: 10.1002/0471141755.ph13b01s50

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

Yang, G. and Huang, M. 2010. Evaluation of Compound Activity Against Hepatitis C Virus in Replicon Systems. Current Protocols in Pharmacology. 50:B:13B.1:13B.1.1–13B.1.21.

Author Information

  1. Achillion Pharmaceuticals, New Haven, Connecticut

Publication History

  1. Published Online: 1 SEP 2010
  2. Published Print: SEP 2010


Described in this unit are protocols for evaluation of new chemical entities for activity against hepatitis C virus (HCV) using HCV replicon systems. While agents designed to target NS3 protease, NS3 helicase, and NS5B RNA polymerase can be evaluated in biochemical assays, it is important to confirm their inhibitory effect on HCV RNA replication using HCV replicon systems, especially since replication involves many components besides these enzymes. Screening of compound libraries using replicon systems has led to the discovery of replication inhibitors, which act through different viral targets. Curr. Protoc. Pharmacol. 50:13B.1.1-13B.1.21. © 2010 by John Wiley & Sons, Inc.


  • HCV;
  • replicon;
  • inhibitor